{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T06:43:56Z","timestamp":1760424236590,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fundamental Research Project of Yunnan Province","award":["202001BB050052","202001BB050052","202001BB050052"],"award-info":[{"award-number":["202001BB050052","202001BB050052","202001BB050052"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["62362066","62362066","U1902201","62362066"],"award-info":[{"award-number":["62362066","62362066","U1902201","62362066"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Yunnan Provincial Science and Technology Department-Yunnan University Double First-Class Joint Fund Key Projects","award":["2019FY003027"],"award-info":[{"award-number":["2019FY003027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cheminform"],"abstract":"<jats:sec>\n                <jats:title>Abstract<\/jats:title>\n                <jats:p>Protein kinases become an important source of potential drug targets. Developing new, efficient, and safe small-molecule kinase inhibitors has become an important topic in the field of drug research and development. In contrast with traditional wet experiments which are time-consuming and expensive, machine learning-based approaches for predicting small molecule inhibitors for protein kinases are time-saving and cost-effective, which are highly desired for us. However, the issue of sample scarcity (known active and inactive compounds are usually limited for most kinases) poses a challenge to the research and development of machine learning-based kinase inhibitors' active prediction methods. To alleviate the data scarcity problem in the prediction of kinase inhibitors, in this study, we present a novel Meta-learning-based inductive logistic matrix completion method for the Prediction of Kinase Inhibitors (MetaILMC). MetaILMC adopts a meta-learning framework to learn a well-generalized model from tasks with sufficient samples, which can fast adapt to new tasks with limited samples. As MetaILMC allows the effective transfer of the prior knowledge learned from kinases with sufficient samples to kinases with a small number of samples, the proposed model can produce accurate predictions for kinases with limited data. Experimental results show that MetaILMC has excellent performance for prediction tasks of kinases with few-shot samples and is significantly superior to the state-of-the-art multi-task learning in terms of AUC, AUPR, etc., various performance metrics. Case studies also provided for two drugs to predict Kinase Inhibitory scores, further validating the proposed method's effectiveness and feasibility.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Scientific contribution<\/jats:title>\n                <jats:p>Considering the potential correlation between activity prediction tasks for different kinases, we propose a novel meta learning algorithm MetaILMC, which learns a prior of strong generalization capacity during meta-training from the tasks with sufficient training samples, such that it can be easily and quickly adapted to the new tasks of the kinase with scarce data during meta-testing. Thus, MetaILMC can effectively alleviate the data scarcity problem in the prediction of kinase inhibitors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13321-024-00838-9","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T09:01:56Z","timestamp":1713258116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Meta-learning-based Inductive logistic matrix completion for prediction of kinase inhibitors"],"prefix":"10.1186","volume":"16","author":[{"given":"Ming","family":"Du","sequence":"first","affiliation":[]},{"given":"XingRan","family":"Xie","sequence":"additional","affiliation":[]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"issue":"5665","key":"838_CR1","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1126\/science.1095920","volume":"303","author":"MEM Noble","year":"2004","unstructured":"Noble MEM, Endicott JA, Johnson LN (2004) Protein kinase inhibitors: insights into drug design from structure[J]. Science 303(5665):1800\u20131805","journal-title":"Science"},{"key":"838_CR2","doi-asserted-by":"publisher","first-page":"104609","DOI":"10.1016\/j.phrs.2019.104609","volume":"152","author":"R Roskoski Jr","year":"2020","unstructured":"Roskoski R Jr (2020) Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res 152:104609","journal-title":"Pharmacol Res"},{"issue":"7","key":"838_CR3","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","volume":"36","author":"P Wu","year":"2015","unstructured":"Wu P, Nielsen TE, Clausen MH (2015) FDA-approved small-molecule kinase inhibitors[J]. Trends Pharmacol Sci 36(7):422\u2013439","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"838_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0804-2","volume":"17","author":"KS Bhullar","year":"2018","unstructured":"Bhullar KS, Lagar\u00f3n NO, McGowan EM et al (2018) Kinase-targeted cancer therapies: progress, challenges, and future directions[J]. Mol Cancer 17(1):1\u201320","journal-title":"Mol Cancer"},{"key":"838_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/978-1-4939-2053-2_10","volume-title":"Receptor tyrosine kinases: structure, functions, and role in human disease","author":"WJ K\u00f6stler","year":"2015","unstructured":"K\u00f6stler WJ, Zielinski CC (2015) Targeting receptor tyrosine kinases in cancer. In: Wheeler DL, Yarden Y (eds) Receptor tyrosine kinases: structure, functions, and role in human disease. Spring, New York p, pp 225\u2013278"},{"issue":"3","key":"838_CR6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1021\/acs.jmedchem.0c01511","volume":"64","author":"Z Xie","year":"2021","unstructured":"Xie Z, Yang X, Duan Y et al (2021) Small-molecule kinase inhibitors for the treatment of nononcologic diseases[J]. J Med Chem 64(3):1283\u20131345","journal-title":"J Med Chem"},{"issue":"14","key":"838_CR7","doi-asserted-by":"publisher","first-page":"4409s","DOI":"10.1158\/1078-0432.CCR-06-0087","volume":"12","author":"R Dziadziuszko","year":"2006","unstructured":"Dziadziuszko R, Hirsch FR, Varella-Garcia M et al (2006) Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization\u2014why, when, and how?[J]. Clin Cancer Res 12(14):4409s\u20134415s","journal-title":"Clin Cancer Res"},{"issue":"1","key":"838_CR8","first-page":"26","volume":"27","author":"J Ali","year":"2017","unstructured":"Ali J, Khan SA, Shan-e-Rauf AM et al (2017) Comparative analysis of fluorescence in situ hybridization and real-time polymerase chain reaction in diagnosis of chronic myeloid leukemia[J]. J Coll Phys Surg Pak 27(1):26\u201329","journal-title":"J Coll Phys Surg Pak"},{"issue":"9","key":"838_CR9","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1038\/s41375-022-01660-8","volume":"36","author":"S Soverini","year":"2022","unstructured":"Soverini S, De Santis S, Martelli M et al (2022) Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR: ABL1 kinase domain mutations in chronic myeloid leukemia[J]. Leukemia 36(9):2250\u20132260","journal-title":"Leukemia"},{"issue":"6","key":"838_CR10","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1021\/acs.jcim.1c00320","volume":"61","author":"MF Sanner","year":"2021","unstructured":"Sanner MF, Zoghebi K, Hanna S et al (2021) Cyclic peptides as protein kinase inhibitors: structure\u2013activity relationship and molecular modeling[J]. J Chem Inf Model 61(6):3015\u20133026","journal-title":"J Chem Inf Model"},{"issue":"2","key":"838_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2174\/2213275912666191102162959","volume":"28","author":"G Bitencourt-Ferreira","year":"2021","unstructured":"Bitencourt-Ferreira G, da Duarte Silva A, Filgueira AJ (2021) Application of machine learning techniques to predict binding affinity for drug targets: a study of cyclin-dependent kinase 2[J]. Curr Med Chem 28(2):253\u2013265","journal-title":"Curr Med Chem"},{"issue":"5","key":"838_CR12","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41587-020-00778-3","volume":"39","author":"M Kuljanin","year":"2021","unstructured":"Kuljanin M, Mitchell DC, Schweppe DK et al (2021) Reimagining high-throughput profiling of reactive cysteines for cell-based screening of large electrophile libraries[J]. Nat Biotechnol 39(5):630\u2013641","journal-title":"Nat Biotechnol"},{"issue":"3","key":"838_CR13","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/ijms22031180","volume":"22","author":"A Roy","year":"2021","unstructured":"Roy A, Groten J, Marigo V et al (2021) Identification of novel substrates for cGMP dependent protein kinase (PKG) through kinase activity profiling to understand its putative role in inherited retinal degeneration[J]. Int J Mol Sci 22(3):1180","journal-title":"Int J Mol Sci"},{"issue":"6","key":"838_CR14","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1021\/acs.jmedchem.0c01904","volume":"64","author":"JWM Nissink","year":"2021","unstructured":"Nissink JWM, Bazzaz S, Blackett C et al (2021) Generating Selective leads for mer kinase inhibitors\u2014example of a comprehensive lead-generation strategy[J]. J Med Chem 64(6):3165\u20133184","journal-title":"J Med Chem"},{"issue":"3","key":"838_CR15","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.chembiol.2021.02.012","volume":"28","author":"S Ziegler","year":"2021","unstructured":"Ziegler S, Sievers S, Waldmann H (2021) Morphological profiling of small molecules[J]. Cell Chem Biol 28(3):300\u2013319","journal-title":"Cell Chem Biol"},{"key":"838_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.9130","author":"HS Beeston","year":"2021","unstructured":"Beeston HS, Klein T, Norman RA et al (2021) Validation of ion mobility spectrometry-mass spectrometry as a screening tool to identify type II kinase inhibitors of FGFR1 kinase[J]. Rapid Commun Mass Spectrom. https:\/\/doi.org\/10.1002\/rcm.9130","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"11","key":"838_CR17","doi-asserted-by":"publisher","first-page":"109233","DOI":"10.1016\/j.celrep.2021.109233","volume":"35","author":"SA Khan","year":"2021","unstructured":"Khan SA, Park K, Fischer LA et al (2021) Probing the signaling requirements for naive human pluripotency by high-throughput chemical screening[J]. Cell Rep 35(11):109233","journal-title":"Cell Rep"},{"issue":"1","key":"838_CR18","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1021\/acs.jmedchem.6b01611","volume":"60","author":"B Merget","year":"2017","unstructured":"Merget B, Turk S, Eid S et al (2017) Profiling prediction of kinase inhibitors: toward the virtual assay[J]. J Med Chem 60(1):474\u2013485","journal-title":"J Med Chem"},{"issue":"3","key":"838_CR19","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1021\/acs.jcim.8b00640","volume":"59","author":"APA Janssen","year":"2018","unstructured":"Janssen APA, Grimm SH, Wijdeven RHM et al (2018) Drug discovery maps, a machine learning model that visualizes and predicts kinome\u2013inhibitor interaction landscapes[J]. J Chem Inf Model 59(3):1221\u20131229","journal-title":"J Chem Inf Model"},{"issue":"16","key":"838_CR20","doi-asserted-by":"publisher","first-page":"8723","DOI":"10.1021\/acs.jmedchem.9b00855","volume":"63","author":"X Li","year":"2019","unstructured":"Li X, Li Z, Wu X et al (2019) Deep learning enhancing kinome-wide polypharmacology profiling: model construction and experiment validation[J]. J Med Chem 63(16):8723\u20138737","journal-title":"J Med Chem"},{"issue":"5","key":"838_CR21","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1021\/acs.jcim.5b00646","volume":"56","author":"A Bora","year":"2016","unstructured":"Bora A, Avram S, Ciucanu I et al (2016) Predictive models for fast and effective profiling of kinase inhibitors[J]. J Chem Inf Model 56(5):895\u2013905","journal-title":"J Chem Inf Model"},{"issue":"4","key":"838_CR22","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1021\/ci200607f","volume":"52","author":"S Niijima","year":"2012","unstructured":"Niijima S, Shiraishi A, Okuno Y (2012) Dissecting kinase profiling data to predict activity and understand cross-reactivity of kinase inhibitors[J]. J Chem Inf Model 52(4):901\u2013912","journal-title":"J Chem Inf Model"},{"issue":"2","key":"838_CR23","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1021\/acsomega.9b00298","volume":"4","author":"R Rodriguez-Perez","year":"2019","unstructured":"Rodriguez-Perez R, Bajorath J (2019) Multitask machine learning for classifying highly and weakly potent kinase inhibitors[J]. ACS Omega 4(2):4367\u20134375","journal-title":"ACS Omega"},{"issue":"2","key":"838_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/bioinformatics\/bty582","volume":"35","author":"YC Lo","year":"2019","unstructured":"Lo YC, Liu T, Morrissey KM et al (2019) Computational analysis of kinase inhibitor selectivity using structural knowledge[J]. Bioinformatics 35(2):235\u2013242","journal-title":"Bioinformatics"},{"issue":"22\u201323","key":"838_CR25","first-page":"5481","volume":"36","author":"C Shen","year":"2020","unstructured":"Shen C, Luo J, Ouyang W et al (2020) IDDkin: network-based influence deep diffusion model for enhancing prediction of kinase inhibitors[J]. Bioinformatics 36(22\u201323):5481\u20135491","journal-title":"Bioinformatics"},{"issue":"4","key":"838_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nchembio.530","volume":"7","author":"JT Metz","year":"2011","unstructured":"Metz JT, Johnson EF, Soni NB et al (2011) Navigating the kinome[J]. Nat Chem Biol 7(4):200\u2013202","journal-title":"Nat Chem Biol"},{"key":"838_CR27","unstructured":"Finn C, Abbeel P, Levine S. Model-agnostic meta-learning for fast adaptation of deep networks[C]\/\/International conference on machine learning. PMLR, 2017: 1126\u20131135."},{"issue":"8","key":"838_CR28","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1093\/bioinformatics\/btz965","volume":"36","author":"J Li","year":"2020","unstructured":"Li J, Zhang S, Liu T et al (2020) Neural inductive matrix completion with graph convolutional networks for miRNA-disease association prediction[J]. Bioinformatics 36(8):2538\u20132546","journal-title":"Bioinformatics"},{"issue":"6","key":"838_CR29","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/bioinformatics\/btaa880","volume":"37","author":"K Huang","year":"2021","unstructured":"Huang K, Xiao C, Glass LM et al (2021) MolTrans: molecular inter-action transformer for drug\u2013target interaction prediction [J]. Bioinformatics 37(6):830\u2013836","journal-title":"Bioinformatics"},{"key":"838_CR30","doi-asserted-by":"crossref","unstructured":"Guo Z, Zhang C, Yu W, et al. Few-shot graph learning for molecular property prediction[C] \/\/Proceedings of the Web Conference 2021. 2021: 2559\u20132567.","DOI":"10.1145\/3442381.3450112"},{"key":"838_CR31","doi-asserted-by":"publisher","DOI":"10.1089\/cmb.2022.0241","author":"A Pande","year":"2022","unstructured":"Pande A, Patiyal S, Lathwal A et al (2022) Pfeature: a tool for computing wide range of protein features and building prediction models[J]. J Comput Biol. https:\/\/doi.org\/10.1089\/cmb.2022.0241","journal-title":"J Comput Biol"},{"issue":"24","key":"838_CR32","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant philadelphia chromosome\u2013positive leukemias[J]. N Engl J Med 354(24):2531\u20132541","journal-title":"N Engl J Med"},{"issue":"2","key":"838_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma[J]. N Engl J Med 356(2):115\u2013124","journal-title":"N Engl J Med"},{"issue":"5","key":"838_CR34","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.chembiol.2019.02.018","volume":"26","author":"N Moret","year":"2019","unstructured":"Moret N, Clark NA, Hafner M et al (2019) Cheminformatics tools for analyzing and designing optimized small-molecule collections and libraries[J]. Cell Chem Biol 26(5):765\u2013777","journal-title":"Cell Chem Biol"},{"key":"838_CR35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s43018-020-00169-2","volume":"2","author":"J Ma","year":"2021","unstructured":"Ma J, Fong SH, Luo Y et al (2021) Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients. Nat Cancer 2:233\u2013244. https:\/\/doi.org\/10.1038\/s43018-020-00169-2","journal-title":"Nat Cancer"},{"key":"838_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-17083-7","author":"Y Luo","year":"2019","unstructured":"Luo Y, Ma J, Zhao X et al (2019) Mitigating data scarcity in protein binding prediction using meta-learning[C]. RECOMB. https:\/\/doi.org\/10.1007\/978-3-030-17083-7","journal-title":"RECOMB"}],"container-title":["Journal of Cheminformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13321-024-00838-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13321-024-00838-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13321-024-00838-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T21:03:28Z","timestamp":1722978208000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcheminf.biomedcentral.com\/articles\/10.1186\/s13321-024-00838-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["838"],"URL":"https:\/\/doi.org\/10.1186\/s13321-024-00838-9","relation":{},"ISSN":["1758-2946"],"issn-type":[{"type":"electronic","value":"1758-2946"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"assertion":[{"value":"17 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"(Applicable for both human and\/ or animal studies. Ethical committees, Internal Review Boards, and guidelines followed must be named. When applicable, additional headings with statements on consent to participate and consent to publish are also required).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}